Table 1.
Clinicopathological parameters for resected PDAC (n = 98).
| Demographics | n | (%) |
|---|---|---|
| Age, median [years] | 68 | (34–80) |
| Sex, male | 50 | (51.0%) |
| Preoperative Risk Factors | ||
| CTCs ≥ 1/7.5 mL | 7 | (7.1%) |
| CA19–9 ≥ 200 kU/l | 31/74 | (41.9%) 24 missing |
| Tumour size on imaging> 25 mm | 39/97 | (40.2%) 1 missing |
| Bilirubin > 50 µmol/L | 75/94 | (79.8%) 4 missing |
| Treatment | ||
| Neoadjuvant chemotherapy: | ||
| GEM | 3 | (3.0%) |
| FOLFIRINOX | 1 | (1.0%) |
| Operation: | ||
| PPPD | 77 | (78.6%) |
| PD | 13 | (13.3%) |
| Total pancreatectomy | 8 | (8.2%) |
| Venous resection | 36 | (36.7%) |
| Adjuvant chemotherapy: | ||
| FLV | 53 | (54.1%) |
| GEM | 6 | (6.1%) |
| FLOX | 3 | (3.1%) |
| none | 36 | (36.7%) |
| Histopathologic results | ||
| Pancreatobiliary type | 97 | (99%) |
| Intestinal type | 1 | (1.0%) |
| UICC-stage (V7): | ||
| Ib | 2 | (2.0%) |
| IIa | 23 | (23.5%) |
| IIb | 73 | (74.5%) |
| pN1-status | 73 | (74,5%) |
| R1-status | 61 | (62.2%) |
| Vascular infiltration | 65 | (66.3%) |
| Perineural infiltration | 91 | (92.9%) |
FLV: 5-fluorouracil and folinic acid; FLOX: 5-fluorouracil, folinic acid and oxaliplatine; FOLFIRINOX: 5-fluorouracil, folinic acid, irinotecan and oxaliplatin; GEM: gemcitabine; PD: pancreatoduodenectomy; PPPD: pylorus preserving PD.